nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Activation of the contact phase of the coagulation, of the kinin system and of the complement cascade by streptokinase in acute myocardial infarction
|
Hoffmeister, H.M. |
|
1997 |
11 |
S2 |
p. 149-152 4 p. |
artikel |
2 |
Acute coronary syndromes and their pathophysiological basis
|
Huber, K. |
|
1997 |
11 |
S2 |
p. 1-9 9 p. |
artikel |
3 |
Acute reperfusion injury of myocardium
|
Piper, H.M. |
|
1997 |
11 |
S2 |
p. 113-115 3 p. |
artikel |
4 |
Adenovirus-mediated gene transfer: biological and clinical applications
|
Denger, S. |
|
1997 |
11 |
S2 |
p. 177-179 3 p. |
artikel |
5 |
Antiplatelet agents in clinical practice: an economic perspective
|
Muhlestein, J.B. |
|
1997 |
11 |
S2 |
p. 133-136 4 p. |
artikel |
6 |
Antithrombotic gene therapy
|
Gerard, R.D. |
|
1997 |
11 |
S2 |
p. 171-176 6 p. |
artikel |
7 |
Best strategy for reperfusion for acute myocardial infarction: direct PTCA
|
Grover, R. |
|
1997 |
11 |
S2 |
p. 71-74 4 p. |
artikel |
8 |
Clinical trials to limit reperfusion injury
|
Smalling, R.W. |
|
1997 |
11 |
S2 |
p. 123-124 2 p. |
artikel |
9 |
Clinical use of intravenous glycoprotein IIb/IIIa inhibitors
|
Stouffer, G.A. |
|
1997 |
11 |
S2 |
p. 129-132 4 p. |
artikel |
10 |
Comparative cross-over study of the effects of lisinopril and doxazosin on insulin, glucose and lipoprotein metabolism and the endogenous fibrinolytic system
|
Zehetgruber, M. |
|
1997 |
11 |
S2 |
p. 153-158 6 p. |
artikel |
11 |
Complex causes of fatal myocardial infarction
|
James, T.N. |
|
1997 |
11 |
S2 |
p. 11-15 5 p. |
artikel |
12 |
Construction of an activated, high-affinity GP IIb/IIIa (αIIbβ3) integrin receptor and its use for the determination of the role of affinity and cytoskeletal anchorage in cell adhesion, cell migration and fibronectin matrix assembly
|
Peter, K. |
|
1997 |
11 |
S2 |
p. 193-196 4 p. |
artikel |
13 |
Effects of fluid shear stress on atherogenesis and hemostasis
|
Ruef, J. |
|
1997 |
11 |
S2 |
p. 159-164 6 p. |
artikel |
14 |
Hypoxia and the vascular endothelium
|
Schmedtje Jr., J.F. |
|
1997 |
11 |
S2 |
p. 125-127 3 p. |
artikel |
15 |
Individualized care for acute myocardial infarction: which patient benefits most from which treatment option?
|
Verheugt, F.W.A. |
|
1997 |
11 |
S2 |
p. 79-81 3 p. |
artikel |
16 |
Insights from gene-inactivation studies of the coagulation and plasminogen
|
Carmeliet, P. |
|
1997 |
11 |
S2 |
p. 181-191 11 p. |
artikel |
17 |
Interpretation of results of clinical trials in coronary thrombolysis
|
Sobel, B.E. |
|
1997 |
11 |
S2 |
p. 17-21 5 p. |
artikel |
18 |
Long-term intermittent urokinase therapy in end-stage coronary artery disease: effects on hemodynamics and ischemic left heart failure
|
Leschke, M. |
|
1997 |
11 |
S2 |
p. 101-105 5 p. |
artikel |
19 |
Mechanism of reperfusion damage after thrombolysis and ‘direct PTCA’
|
Darius, H. |
|
1997 |
11 |
S2 |
p. 117-121 5 p. |
artikel |
20 |
PAI-1 in thrombosis and arteriosclerosis
|
Fujii, S. |
|
1997 |
11 |
S2 |
p. 137-140 4 p. |
artikel |
21 |
Pharmacology and clinical efficacy of reteplase
|
Bode, C. |
|
1997 |
11 |
S2 |
p. 29-33 5 p. |
artikel |
22 |
Rationale for the bolus administration of fibrin-specific thrombolytic agents
|
Agnelli, G. |
|
1997 |
11 |
S2 |
p. 23-27 5 p. |
artikel |
23 |
Recombinant staphylokinase for thrombolytic therapy
|
Vanderschueren, S. |
|
1997 |
11 |
S2 |
p. 39-44 6 p. |
artikel |
24 |
Regulation of the synthesis of plasminogen activator inhibitor type 1 (PAI-1): pathogenetic mechanism of atherosclerosis in diabetes mellitus?
|
Nordt, T.K. |
|
1997 |
11 |
S2 |
p. 141-147 7 p. |
artikel |
25 |
Relative safety and complication profiles of thrombolysis and primary angioplasty in acute myocardial infarction
|
de Bono, D.P. |
|
1997 |
11 |
S2 |
p. 75-78 4 p. |
artikel |
26 |
Reteplase mortality studies
|
Hampton, J.R. |
|
1997 |
11 |
S2 |
p. 35-38 4 p. |
artikel |
27 |
Signal transduction via urokinase receptor: is a transmembrane adapter molecule really necessary?
|
Dumler, I. |
|
1997 |
11 |
S2 |
p. 165-169 5 p. |
artikel |
28 |
Surgical alternatives in pulmonary embolism
|
Jakob, H. |
|
1997 |
11 |
S2 |
p. 197-203 7 p. |
artikel |
29 |
Targeting of thrombolytic and antithrombotic agents
|
Bode, C. |
|
1997 |
11 |
S2 |
p. 63-70 8 p. |
artikel |
30 |
Thrombolysis and modern anticoagulation in unstable angina pectoris
|
Frey, N. |
|
1997 |
11 |
S2 |
p. 107-111 5 p. |
artikel |
31 |
Thrombolysis during cardiopulmonary resuscitation
|
Böttiger, B.W. |
|
1997 |
11 |
S2 |
p. 93-100 8 p. |
artikel |
32 |
Thrombolytic therapy in right ventricular infarction
|
Zehender, M. |
|
1997 |
11 |
S2 |
p. 83-87 5 p. |
artikel |
33 |
Thrombolytic therapy of acute myocardial infarction with saruplase, a single-chain urokinase-type plasminogen activator (scu-PA) from recombinant bacteria
|
Tebbe, U. |
|
1997 |
11 |
S2 |
p. 45-54 10 p. |
artikel |
34 |
Update on the toxicology and pharmacology of rDSPA alpha 1 (Bat-PA) in animals and humans
|
Gulba, D.C. |
|
1997 |
11 |
S2 |
p. 55-62 8 p. |
artikel |
35 |
Update on thrombolytic therapy in ischemic stroke
|
Hacke, W. |
|
1997 |
11 |
S2 |
p. 89-92 4 p. |
artikel |